Please ensure Javascript is enabled for purposes of website accessibility

Why ChromaDex Stock Blasted Almost 30% Higher Today Before Falling Into the Red

By Eric Volkman - Mar 10, 2021 at 3:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A major deal with a giant retailer wasn't enough to sustain the price pop.

What happened

Bioscience company ChromaDex (CDXC 1.73%) got off to a roaring start on Wednesday, rising nearly 29% in early trading, before melting to a 2.3% decline by midafternoon. A big distribution deal was the reason for the sudden pop.

So what

This morning, ChromaDex announced that its Tru Niagen dietary supplement will hit the shelves of Walmart (WMT -2.74%) beginning in June. Tru Niagen will be sold in two packaging options in the 3,000 stores where the product is being distributed. Remote shoppers can also purchase it through the Walmart e-commerce portal.

ChromaDex claims that Tru Niagen, which is approved by the Food and Drug Administration, increases nicotinamide adenine dinucleotide (NAD) in the body. This chemical helps the body produce energy, and it declines with age. It can also be eroded, says ChromaDex, by stressors such as overexercising, lack of sleep, and alcohol consumption. 

A researcher studying a sample in a petri dish.

Image source: Getty Images.

The product's main ingredient, Niagen, is the substance that boosts NAD, according to ChromaDex. It is patented by the company.

ChromaDex has not offered any forecasts as to how the Walmart deal will affect its fundamentals.

Now what

That morning euphoria might have been tempered by the realization that ChromaDex is still very unprofitable; its net losses have ranged from $4.2 million to almost $8.9 million over the last four quarters, on revenue that reached as much as $15.3 million. The Walmart news is certainly encouraging, but it seems the healthcare company needs a bigger portfolio to become a more-compelling investment case.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ChromaDex Corporation Stock Quote
ChromaDex Corporation
$1.76 (1.73%) $0.03
Wal-Mart Stores, Inc. Stock Quote
Wal-Mart Stores, Inc.
$119.07 (-2.74%) $-3.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.